62 completed, 13 terminated, 3 withdrawn, 1 unknown. 33 Phase 3, 27 Phase 1, 11 Phase 2, 4 Phase 4, 1 Not applicable.
Follow Purdue Pharma LP: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Evaluation of Nalmefene Formulations Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection - Opioid Overdose | Phase 1 | Completed | Knoa Pharma LLC | 13 | 2026-02-06 | 2026-06-05 |
| Clinical Outcomes From Nalmefene Nalmefene Hydrochloride Injection, Naloxone Hydrochloride Injection - Opioid Overdose | Phase 4 | Withdrawn | Purdue Pharma LP | 2023-06-01 | 2023-07-12 | |
| Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg Nalmefene HCl injection, Naloxone HCl intranasal - Opioid Overdose | Phase 1 | Completed | Purdue Pharma LP | 24 | 2022-10-03 | 2025-07-03 |
| Study of V117957 in Overactive Bladder Syndrome V117957, Placebo - Overactive Bladder Syndrome | Phase 1 | Completed | Imbrium Therapeutics | 51 | 2022-06-30 | 2025-06-26 |
| Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome V117957, Placebo - Interstitial Cystitis/Bladder Pain Syndrome | Phase 1 | Completed | Imbrium Therapeutics | 47 | 2022-05-26 | 2026-03-09 |
| Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children Adhansia XR - Attention Deficit/Hyperactivity Disorder | Phase 4 | Terminated | Purdue Pharma LP | 103 | 2021-08-03 | 2023-08-22 |
| Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) Adhansia XR, Concerta - Attention-Deficit/Hyperactivity Disorder | Phase 4 | Terminated | Purdue Pharma LP | 267 | 2020-07-30 | 2023-07-27 |
| Current Procedural Sedation Practices in a Canadian Community Emergency Department Retrospective cohort - Conscious Sedation | Unknown | Amber Graystone | 300 | 2019-11-30 | 2019-11-21 | |
| Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation V117957 tablets, Placebo - Insomnia | Phase 2 | Completed | Imbrium Therapeutics | 114 | 2019-09-23 | 2023-09-18 |
| Study of Lemborexant-Alcohol Interaction in Healthy Subjects Lemborexant, Alcohol, Placebo - Healthy Subjects | Phase 1 | Completed | Eisai Inc. | 24 | 2018-03-12 | 2018-10-17 |
| Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea Placebo, Lemborexant 10 mg, Lemborexant 25 mg - Obstructive Sleep Apnea, Healthy Subjects | Phase 1 | Completed | Eisai Inc. | 146 | 2018-02-21 | 2020-02-17 |
| Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment Lemborexant - Renal Impairment | Phase 1 | Completed | Eisai Inc. | 16 | 2018-02-07 | 2020-03-12 |
| Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects lemborexant, Loestrin, famotidine - Healthy Subjects | Phase 1 | Completed | Eisai Inc. | 50 | 2018-02-05 | 2018-09-06 |
| Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects Lemborexant - Hepatic Impairment | Phase 1 | Completed | Eisai Inc. | 24 | 2018-01-26 | 2020-03-20 |
| Effect of Methylphenidate on Cancer-related Cognitive Impairment Methylphenidate HCl 10Mg SR, Placebo Group - Breast Cancer Female, Cancer-Related Condition | Phase 2 | Terminated | CHU de Quebec-Universite Laval | 20 | 2017-10-09 | 2023-03-23 |
| Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System WHT - Chronic Pain | Completed | Purdue Pharma LP | 420 | 2017-10-05 | 2024-09-19 | |
| A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users Zolpidem tablets, Suvorexant tablets, over-encapsulated, Lemborexant tablets - Insomnia Disorders | Phase 1 | Completed | Eisai Inc. | 39 | 2017-04-19 | 2020-06-29 |
| A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee V120083, Naproxen, Placebo - Osteo Arthritis Knee | Phase 2 | Completed | Purdue Pharma LP | 291 | 2017-03-14 | 2019-02-12 |
| Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children HYD tablets - Pain | Phase 2 | Withdrawn | Purdue Pharma LP | 2017-01-01 | 2017-04-24 | |
| Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg - Irregular Sleep-Wake Rhythm Disorder | Phase 2 | Completed | Eisai Inc. | 63 | 2016-12-20 | 2021-05-17 |
Showing 20 of 79. Sign in to see all of them.
Chronic Pain (12) · Osteoarthritis (12) · Pain (12) · Attention Deficit Disorder with Hyperactivity (7) · Low Back Pain (7) · Osteoarthritis, Knee (4) · Pain, Postoperative (4) · Opiate Overdose (3) · Agnosia (2) · Back Pain (2) · Constipation (2) · Sleep Initiation and Maintenance Disorders (2) · Acute Pain (1) · Breast Neoplasms (1) · Cognitive Dysfunction (1)
Buprenorphine (20) · Oxycodone (13) · lemborexant (8) · Methylphenidate (3) · Moxifloxacin (3) · Naproxen (3) · nalmefene (3) · 4-(3-chloro-5-(1,2-dihydroxyethyl)-2-pyridyl)-N-(5-(trifluoromethyl)-2-pyridyl)-3,6-dihydro-2H-pyridine-1-carboxamide (2) · Hydrocodone (2) · Naloxone (2) · Tablets (2) · Acetaminophen (1) · Capsaicin (1) · Celecoxib (1) · Ethanol (1)
United States (69) · Canada (7) · United Kingdom (3) · Israel (2) · New Zealand (2) · Australia (1) · Czechia (1) · Denmark (1) · Finland (1) · Greece (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1)
Joseph Reiz (3) · Brian Brooks, MD (1) · Bruno Gagnon (1) · Chistopher Gibbins, MD (1) · David A Seminowicz, PhD (1) · Deborah L Steiner, MD, MS (1) · Grant Iverson, MD (1) · Gregory B. Hammer, MD (1) · John J Han, MD (1) · Li Ying Lu, MD (1) · Margaret D. Weiss, MD, Ph.D (1) · Martin Hale, MD (1) · Sarah O'Keefe, BSN (1) · Thomas Alfieri, PhD (1)
PMID 28072811, PMID 34637343, PMID 34714112, PMID 39120786, PMID 21807566, PMID 21945130, PMID 22409388, PMID 22845044, PMID 26111544, PMID 26312961, PMID 26681111, PMID 26749219, PMID 27927048, PMID 30597112, PMID 32022664, PMID 34057707, PMID 35201607, PMID 35748777, PMID 36971690, PMID 37883189, PMID 40848323, PMID 41342306
2017 (1)